Afrezza, a needle-free inhalable insulin spray, has been approved in India, offering a convenient and painless solution for managing diabetes.

The most common adverse effects reported during clinical trials were hypoglycemia, headache, dizziness, and injection-site ... NPH = isophane insulin human, NR = not recorded, OL = open-label ...

I remember carrying out an audit of diabetes in my practice in the early 1990s and we had 47 patients with diabetes, which ...

In dogs with pancreatitis, the digestive enzymes don’t flow to the intestines to digest food as they should but instead start ...

The 26-week, open-label clinical trial randomized 230 pediatric subjects to one of two groups: Afrezza or multiple daily injections ... Afrezza (insulin human) Inhalation Powder is a rapid ...

Extending the human healthspan would bring happiness, vitality, productivity and meaning to millions of older adults. It ...

Novo Nordisk also spent several years trying to develop an oral formulation of insulin that could replace injections ... pig liver into a brain-dead human patient.

Learn about the 4 essential types of diabetes, their unique characteristics, risk factors, and management strategies to ...

Later, synthetic ‘human’ insulin was developed in 1978 and then ... such as the approval of Novo Nordisk’s Ozempic (semaglutide injection) and Eli Lilly’s Trulicity (dulaglutide).

The AI in Life Science Market is anticipated to experience a remarkable compound annual growth rate (CAGR) of around 25% in ...

A Pittsburgh firm is harnessing artificial intelligence to make it easier for military aircraft to land on ships at sea.

However, the reluctance in adoption of rapid acting insulin due to the side effect, such as hypoglycemia, may hinder the growth of the industry. Conversely, untapped market and undiagnosed population ...